LAG3 and neoplasm: A phase I trial indicated that tebotelimab blocks both the PD-1 and LAG-3 signaling pathways, displaying preliminary anti-tumor activity, particularly in ovarian epithelial cancer (PR, 11.1%), triple-negative BC (PR, 6.5%), and ICI-naïve NSCLC (ORR, 14.2%; CR, 7.1%).